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Advances made in the ﬁeld of hematopoietic stem cell transplantations (HSCT) over the past 20 years may
have had an impact on the distribution of posttransplantation infections. We sought to retrospectively
analyze the epidemiology and risk factors for bacterial, fungal, and viral infections in children after allogeneic
HSCT in a cohort of 759 children who underwent allogeneic HSCT in a single institution between 1990 and
2009. The association between infections and risk factors of interest at 0 to 30 days, 31 to 100 days, and 101
days to 2 years posttransplantation was evaluated using logistic regression. Difference among the subtypes
within each category was studied. There were 243 matched-related donors, 239 matched-unrelated donors
(MUDs), and 176 haploidentical donor transplantations. Era of transplantation (0-30 days), peripheral blood
stem cell product, acute graft-versus-host disease (aGVHD; 31-100 days), and chronic GVHD (cGVHD; 101-
730 days) were associated with higher risk for bacterial infections at the respective time periods. Patients
with aGVHD (31-100 days), cGVHD, and older age (101-730 days) were at higher risk for fungal infections.
Cytomegalovirus (CMV) donor/recipient (D/R) serostatus (0-100 days), era of transplantation, MUD HSCT
(31-100 days), and cGVHD (101-730 days), inﬂuenced viral infections. Gram-positive outnumbered gram-
negative bacterial infections; aspergillosis and candidemia were equally prevalent in all time periods. Hap-
loidentical donor HSCT was not associated with an increased risk of infections. There seems to be
a continuum in the timeline of infections posttransplantation, with bacterial, fungal, and viral infections
prevalent in all time periods, particularly late after the transplantation, the risk affected by GVHD, CMV,
D/R status, product type, older age, and use of unrelated donors.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION of pre-emptive therapy, disease due to CMV [3], and herpes
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an established treatment modality for patients
with certain hematologic malignancies and for many
congenital and acquired disorders of the hematopoietic
system. Infections contribute signiﬁcantly to the morbidity
and mortality from this procedure. The manner in which the
transplantation is performed has changed substantially over
the past 2 decades. This may have had an impact on the type
of pathogens and timeline of infections posttransplantation.
Data predominantly from the adult literature show that
gram-positive (GP) and gram-negative (GN) bacteria [1],
Candida and Aspergillus spp [2], are major pathogens in the
pre-engraftment phase. With neutrophil recovery, bacterial
infections decrease, and infections by cytomegalovirus (CMV)
[3] and fungi predominate, particularly in association with
graft-versus-host disease (GVHD) [4]. The risk of invasive
fungal infections in the late recovery phase increases with
age, CMV infection, GVHD, and in recipients of matched-
unrelated donor (MUD) transplantation [5,6]. With the useedgments on page 100.
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Haploidentical donor transplantations have been reported to
inﬂuence the risk of fungal [8] and adenoviral (ADV) [9]
infections in this phase. Total-body irradiation (TBI) has
been associated with an increased risk of symptomatic para-
inﬂuenza virus (PIV) [10] and ADV infection [11].
Thus, there is a complex interplay of factors including
patient demographics, neutropenia, GVHD, transplantation
modality, TBI, product type, CMV donor/recipient (D/R)
status, and era of transplantation, contributing to infection
risk. The effect of these factors on risk of bacterial, fungal, and
viral infection, at 0 to 30 days, 31 to 100 days, and 101 days to
2 years posttransplantation, after adjusting for confounding
variables, has not been well studied both in children and
adults. This is the largest retrospective study providing
a timeline of infections in young HSCT recipients.
PATIENTS AND METHODS
This retrospective cohort consisted of 786 patients who underwent
a ﬁrst allogeneic HSCT over a 20-year period (January 1990 through
December 2009) at St. Jude Children’s Research Hospital (SJCRH). Patients
who were older than 21 years of age at transplantation (19 patients) and
those who underwent a cord blood transplantation (8 patients) were
excluded. A total of 759 patients were included in this analysis. The study
was approved by the SJCRH Institutional Review Board. Patients were fol-
lowed for 10 years after transplantation or until age 18 years whichever was
later. Follow-up was frequent in the ﬁrst 2 years after transplantation and
yearly thereafter. The mean duration of follow-up for surviving patients was
7.96 years (range, 0.21-19.91 years).Transplantation.
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Microbiologic records were reviewed to identify patients with docu-
mented bacterial, fungal, and viral infections as diagnosed by culture
(bacteria, fungi, viruses), direct ﬂuorescent antibody testing, and PCR
(viruses). Infectionwas deﬁned as isolation or detection of an organism that
was associated with symptoms or disease and included fungal and viral
pathogens detected on pre-emptive screening. Colonization detected in
surveillance cultures and positive blood cultures due to contaminationwere
not considered as infections. Infections with the same organism occurring
more than 14 days after the last negative culture or diagnostic test were
recorded as 2 separate infectious episodes. Only the ﬁrst episode of
bacteremia and the ﬁrst episode of GP, GN, yeast, mold, and speciﬁc viral
infection in a given patient during the speciﬁed time period was included in
the analyses. The day of onset of infection was deﬁned as the day when the
ﬁrst positive diagnostic sample was collected. Infection as the primary cause
of death was used for analyses. In patients who relapsed from their under-
lying disease, or those with GVHD who died from infection, infection was
not noted as the primary cause of death.
Peripheral blood samples were collected once weekly starting in
February 2000 to prospectively screen for CMV and starting in February and
July 2002 to prospectively screen for Epstein-Barr virus (EBV) and ADV by
quantitative real-time PCR, as previously described [12], using an ABI PRISM
7900HT Sequence Detection system (Applied Biosystems, Foster City, CA).
Before 2000, CMV and ADV were detected by viral blood culture and EBV
using endpoint PCR with detection by Southern blot. Weekly screening on
whole blood for galactomannan was performed from August 2003. Pre-
emptive treatment with ganciclovir, rituximab, and cidofovir was given
based on the results of surveillance testing. Invasive fungal infection was
deﬁned according to accepted criteria [13]. Patients who met the deﬁnition
of possible invasive fungal infections were not included.
Infection Prophylaxis
All patients received prophylaxis against Pneumocystis jirovecii for up to
1 year posttransplantation. Between 1993 and 2000, patients who were
seropositive for CMV or had a seropositive donor received ganciclovir until
day þ120. After 2000, patients at risk for CMV or HSV reactivation received
acyclovir prophylaxis until 1 year posttransplantation. Patients received
antifungal prophylaxis with amphotericin B or lipid-based amphotericin
formulations between 1990 and 2003. Subsequently, prophylaxis was with
echinocandins until engraftment and with voriconazole thereafter. Anti-
bacterial prophylaxis with ﬂuoroquinolones was not given. Patients with
chronic GVHD (cGVHD) received PenVK, cotrimoxazole, acyclovir, and vor-
iconazole prophylaxis.
Era of Transplantation
The populationwas divided into 4 eras. Therewere 111, 218, 219, and 211
patients who underwent HSCT in the eras 1990 to 1994, 1995 to 1999, 2000
to 2004, and 2005 to 2009, respectively. The years 2000 onward represented
a boundary for introduction of peripheral blood stem cell (PBSC) products,
viral monitoring by quantitative real-time PCR, testing for galactomannan,
and use of haploidentical donors.
Transplantation Methods
Transplantation-related variables were abstracted from a prospectively
collected database that included patient demographics, underlying diag-
nosis, remissionstatus, donorandproduct type, CMVD/Rstatus, conditioning
regimen, GVHD prophylaxis, and grading if present. The conditioning and
GVHD prophylaxis have been previously described [14,15]. A regimen based
onTBI and cyclophosphamidewasused for 326of the 427patients (76%)with
acute leukemia. Cyclosporine with methotrexate or mycophenolate mofetil
was predominantly used for GVHD prophylaxis. For haploidentical donor
transplantations, 49 patients (28%) received TBI-based conditioning; the
remaining 127 patients (72%) receivedﬂudarabine, thiotepa, andmelphalan-
based conditioning. Ex vivo T cell depletion of the graft was performed by
anti-T cell Abs and complement in 17 patients (10%) or immune-magnetic
selection using the Miltenyi CliniMACS system (Miltenyi Biotec GmbH,
Teterow, Germany) in 159 patients (90%), respectively. Patients received
GVHD prophylaxis with either a calcineurin inhibitor or mycophenolate
mofetil. The day of engraftmentwas deﬁned as the ﬁrst of 3 consecutive days
of achieving an absolute neutrophil count>500 cells/mL. Assessment of acute
GVHD (aGVHD)was based on consensus criteria [16]. The aGVHDgrade 3 and
4 were classiﬁed as severe. Immunization was according to standard
recommendations [17] starting 1 year posttransplantation.
Statistical Analysis
Theassociation among infections (bacterial, fungal, andviral) and the risk
factors of interest was ﬁrst evaluated using univariate logistic regression. The
risk factors that were evaluated included age at transplantation, era oftransplantation, donor type (haplo vs non-haplo identical), product type
(PBSC vsmarrow), T cell depletion, aGVHD (grade 3 vs others), cGVHD, TBI,
myeloablative vs reduced-intensity conditioning (RIC), CMV D/R status (þ/þ
vs þ/ vs /þ vs /), and MUD vs matched-related donor (MRD) trans-
plantation. To identify the exact sources of differences among eras and CMV
status, Bonferroni correction was used to adjust for multiple comparisons,
and P values were noted to be signiﬁcant at level a ¼ 0.05/6 ¼ 0.008. The
analyses for each type of infection were conducted independently. All the
factors that were signiﬁcant at level a ¼ 0.15 in the univariate analyses were
included in the multiple logistic regression models. The ﬁnal model reports
the results of all factors that remained signiﬁcant at the 5% level.
The association between cumulative incidence of infectious deaths and
the risk factors described above were assessed using Fine and Gray’s
approach [18] within the framework of the Cox proportional hazards model.
Deaths due to any other cause were treated as the competing events, and
research participants alive at the last follow-upwere considered as censored
events.
The cumulative incidence of bacteremia within 30 days post-
transplantationwasdeﬁnedas the time fromthedateof transplantation tothe
ﬁrst episode of bacteremiawithin 30 days, with deathwithin 30 days treated
as a competing event. Patients who survived 30 days posttransplantation
without bacteremia were treated as censored. Cumulative incidence of
bacteremia within 30 days among different eras was estimated as described
by Kalbﬂeisch and Prentice [19] and compared using Gray’s test [20].
Chi-square tests were used to test whether there was a signiﬁcant
difference among the proportions of different subtypes within each category
of interest (ie, GP vs GN; yeast vs mold; Candidemia vs Aspergillus; HSV vs
CMV vs EBV vs ADV; PIV vs inﬂuenza vs respiratory syncytial virus (RSV)
within each time period. SAS version 9.2 (SAS Institute, Cary, NC) and
StatXact (Cytel Corporation, Cambridge, MA) Windows version 8 were used
for statistical analyses.
RESULTS
Patient Characteristics
A total of 759 patients underwent an allogeneic HSCT
between1990 to 2009 at SJCRH. Demographics and patient
characteristics are presented in Table 1.
Infections in the Posttransplantation Period
Infections were documented in 621 patients (82%). GP
infections were more prevalent than GN infections in all
3 time periods posttransplantation (Table 2, Figure 1). There
were 225 patients (30%) with bacteremia including 133
patients with GP and 92 patients with GN bacteremia. The
median onset of bacteremiawas 87 days posttransplantation.
Staphylococcus epidermidis 70 cases (31%) and viridians
streptococci 16 cases (7%) were the most common GP
organisms and Klebsiella spp 18 cases (8%), Escherichia coli 17
cases (8%), and Pseudomonas spp 14 cases (6%) were the most
common GN organisms causing bacteremia. There were 110
patients (14%) with C. difﬁcile infection, and 13 patients (2%)
with Enterococcus spp bacteremia in the entire cohort
including 6 patients with E. faecalis bacteremia, which were
vancomycin-susceptible, and 7 patients with E. faecium
bacteremia, which were vancomycin-resistant.
Yeasts and molds were equally prevalent in all 3 time
periods posttransplantation (Table 2, Figure 1). Candidemia
was detected in 26 patients (3%). Candida albicans and non-
albicans Candida spp were equally prevalent. C. parapsilosis
and C. glabratawere the most common non-albicans Candida
spp isolated. In 49 patients (6%) with proven aspergillosis,
Aspergillus ﬂavus and A. fumigatus were the most frequent
isolates, in 17 and 10 patients, respectively. A probable
diagnosis of invasive fungal infection was made in 40
patients (5%). Candidemia and aspergillosis were equally
prevalent in all 3 time periods posttransplantation (Figure 1).
The distribution of HSV, CMV, EBV, and ADV at 0 to 30
days posttransplantation was signiﬁcant (Figure 1A). HSV
infections were more common than ADV and EBV infections
(P < .0001). Infections by EBV were also less common than
Table 1
Demographics and Characteristics of the Patients Who Underwent an
Allogeneic HSCT at SJCRH Between 1990 and 2009
Characteristic 1990-2009 n ¼ 759 (%)
Mean age (years) 9.4
0-<2 117 (15)
2-<10 286 (38)
10-<18 296 (39)
18-21 60 (8)
Men 450 (59)
Race
White 543 (72)
African American 122 (16)
Other 94 (12)
Diagnosis
ALL 203 (27)
AML 224 (30)
CML 59 (8)
JMML 16 (2)
Lymphoma 24 (3)
MDS 48 (6)
Solid tumors 27 (4)
Hematologic disorders 97 (12)
Immunologic disorders 30 (4)
Metabolic disorders 31 (4)
Donor type
Matched related 243 (32)
Mismatched related 30 (4)
Matched unrelated 239 (32)
Mismatched unrelated 71 (9)
Haploidentical 176 (23)
Product type
HPC-M 576 (76)
HPC-A 183 (24)
CMV status
Dþ/Rþ 212 (28)
Dþ/R 135 (18)
CMV D/R status
D/Rþ 107 (14)
D/R 200 (26)
Not available 105 (14)
Conditioning
TBI-based 497 (65)
Non-TBI-based 262 (35)
Myeloablative 597 (79)
RIC 162 (21)
T cell depletion
Yes 365 (48)
No 394 (52)
Time to engraftment
Within 28 days 662 (87)
After 28 days 71 (9)
Did not engraft 26 (4)
GVHD
Acute 369 (49)
None 390 (51)
Grade I-II 199 (26)
Grade III-IV 170 (23)
Chronic 129 (17)
None 630 (83)
Limited 79 (10)
Extensive 50 (7)
Number of HSCT patients
1990-1994 111 (14)
1995-1999 218 (29)
2000-2004 219 (29)
2005-2009 211 (28)
HSCT indicates hematopoietic stem cell transplantation; SJCRH, St. Jude
Children’s Research Hospital; ALL, acute lymphoblastic leukemia; AML,
acute myeloid leukemia; CML, chronic myeloid leukemia; JMML, juvenile
myelomonocytic leukemia; MDS, myelodysplastic syndrome; HPC-M/A,
human progenitor cellsemarrow/apheresis; CMV D/R, cytomegalovirus
donor/recipient; TBI, total body radiation; RIC, reduced-intensity condi-
tioning; GVHD, graft-versus-host disease.
Data are number of patients (%), unless otherwise indicated.
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CMV, EBV, and ADV at 31 to 100 days posttransplantation
was also signiﬁcant (Figure 1B). CMV infections were more
common than HSV (P < .001), EBV, and ADV (P < .0001). The
distribution of HSV, CMV, EBV, and ADV at 101 days to 2 years
(Figure 1C) was not statistically signiﬁcant. Respiratory tract
infections by RSV were more common than inﬂuenza virus
(P ¼ .01) 31 to 100 days posttransplantation.
CMV D/R status (/þ vs /; þ/þ vs /) increased risk
for CMV viremia (P ¼ .0003; odds ratio [OR], 3.13; 95%
conﬁdence interval [CI], 1.16-8.45; P < .0001; OR, 5.25; 95%
CI, 2.14-12.84), respectively.
Infections 0 to 30 Days after Transplantation
CMV D/R status was a risk factor for viral infections
(Tables 3 and 4). None of the other variables increased the
risk for bacterial or fungal infections on multiple logistic
regression analyses.
Infections Between 31 to 100 Days after Transplantation
Patients with severe aGVHD and those who received
a PBSC product had more bacterial infections and bacteremia
(Table 3). Recipients of haploidentical donor transplantations
were not at increased risk for bacterial infections (P ¼ .36)
or bacteremia (P ¼ .24). Patients with severe aGVHD had
more fungal infections. CMV D/R status was a risk factor for
viral infection (Tables 3 and 4).
Infections 101 Days to 2 Years after Transplantation
Patients with cGVHD had more bacterial infections
(Table 3). The cGVHD and CMV D/R status were associated
with an increased risk for bacteremia; cGVHD and age more
than 10 years at transplantation were associated with
an increased risk for fungal infections. Any cGVHD also
increased the risk for viral infections. Haploidentical donor
transplantation was associated with an increased risk of
chronic (P ¼ .03) but not acute (P ¼ .15) GVHD. However,
recipients of haploidentical donor transplantation and T cell-
depleted donors were not at increased risk for fungal (P¼ .14,
P ¼ .12) or viral (P ¼ .11, P ¼ .31) infections, respectively. RIC
transplantations were not at risk for bacterial, fungal, viral
infections, or bacteremia on univariate logistic regression
analyses.
Inﬂuence of Era of Transplantation on Infections
Patients who underwent a transplantation between 1990
and 1994 had a higher risk of bacterial infections and
bacteremia (Table 3), 0 to 30 days posttransplantation
compared to those who underwent a transplantation
between 1995 and 1999, 2000 and 2004, and 2005 and 2009.
There was no signiﬁcant difference in GP vs GN infections
(P ¼ .43) or bacteremia (P ¼ .55) across the 4 eras. Patients
who underwent a transplantation between 1995 and 1999
had a lower risk of viral infections compared with 2005 to
2009, at 31 to 100 days posttransplantation.
Infections in Recipients of MRD vs MUD HSCT
There were 243 and 239 patients who received an MRD
and MUD HSCT, respectively. Recipients of MRD HSCT had
a lower risk of viral infections 31 to 100 days post-
transplantation (Table 3). Bacterial and fungal infections
were not signiﬁcantly different in the 2 groups.
Table 2
Patients with Infection 0-30 Days, 31-100 Days, and 101 Days-2 Years Posttransplantation
Infection 0-30 Days Posttransplantation
1990-1994 1995-1999 2000-2004 2005-2009 1990-2009
n ¼ 111 n ¼ 218 n ¼ 219 n ¼ 211 n ¼ 759
Bacterial infections
Bacteremia 20 (18) 12 (6) 11 (5) 16 (8) 59 (8)
GP infections 21 (19) 23 (11) 16 (7) 13 (6) 73 (10)
GN infections 9 (8) 5 (2) 5 (2) 6 (3) 25 (3)
Fungal infections
Yeast infections 5 (5) 10 (5) 1 (1) 4 (2) 20 (3)
Mold infections 3 (3) 7 (3) 9 (4) 9 (4) 28 (4)
Candidemia 3 (3) 5 (2) 1 (<1) 3 (1) 12 (2)
Aspergillosis 2 (2) 6 (3) 8 (4) 3 (1) 19 (3)
Viral infections
HSV 9 (8) 31 (14) 7 (3) 5 (2) 52 (7)
CMV 1 (1) 5 (2) 17 (8) 17 (8) 40 (5)
EBV 0 (0) 0 (0) 1 (<1) 5 (2) 6 (1)
ADV 0 (0) 0 (0) 13 (6) 9 (4) 22 (3)
PIV 0 (0) 9 (4) 4 (2) 1 (<1) 14 (2)
Inﬂuenza 2 (2) 1 (<1) 1 (1) 2 (1) 6 (1)
RSV 1 (1) 1 (<1) 2 (1) 3 (1) 7 (1)
Infection 31-100 Days Posttransplantation
1990-1994 1995-1999 2000-2004 2005-2009 1990-2009
n ¼ 106 n ¼ 208 n ¼ 214 n ¼ 207 n ¼ 735
Bacterial infections
Bacteremia 5 (5) 17 (8) 21 (10) 30 (14) 73 (10)
GP infections 19 (18) 26 (12) 31 (14) 36 (17) 112 (16)
GN infections 3 (3) 8 (4) 9 (4) 13 (6) 33 (4)
Fungal infections
Yeast infections 5 (5) 6 (3) 1 (<1) 6 (3) 18 (2)
Mold infections 0 (0) 9 (4) 4 (2) 15 (7) 28 (4)
Candidemia 3 (3) 1 (<1) 0 (0) 1 (<1) 5 (1)
Aspergillosis 0 (0) 7 (3) 2 (1) 2 (1) 11 (1)
Viral infections
HSV 4 (4) 3 (1) 2 (1) 1 (<1) 10 (1)
CMV 4 (4) 2 (1) 29 (14) 30 (14) 65 (9)
EBV 0 (0) 0 (0) 8 (4) 15 (7) 23 (3)
ADV 1 (1) 0 (0) 10 (5) 8 (4) 19 (3)
PIV 1 (1) 4 (2) 3 (1) 0 (0) 8 (1)
Inﬂuenza 0 (0) 0 (0) 1 (1) 0 (0) 1 (<1)
RSV 0 (0) 5 (2) 3 (1) 2 (1) 10 (1)
Infection 101 Days to 2 Years Posttransplantation
1990-1994 1995-1999 2000-2004 2005-2009 1990-2009
n ¼ 79 n ¼ 175 n ¼ 179 n ¼ 189 n ¼ 622
Bacterial infections
Bacteremia 11 (14) 21 (12) 35 (20) 26 (14) 93 (15)
GP infections 17 (22) 21 (12) 35 (20) 48 (25) 121 (19)
GN infections 5 (6) 18 (10) 23 (13) 16 (8) 62 (10)
Fungal infections
Yeast infections 10 (13) 12 (7) 11 (6) 6 (3) 39 (6)
Mold infections 2 (3) 12 (7) 6 (3) 23 (12) 43 (7)
Candidemia 2 (3) 0 (0) 4 (2) 3 (2) 9 (1)
Aspergillosis 1 (1) 7 (4) 4 (2) 7 (4) 19 (3)
Viral infections
HSV 4 (5) 2 (1) 5 (3) 3 (2) 14 (2)
CMV 1 (1) 1 (1) 6 (3) 6 (3) 14 (2)
EBV 0 (0) 0 (0) 5 (3) 2 (1) 7 (1)
ADV 1 (1) 1 (1) 11 (6) 7 (4) 20 (3)
PIV 3 (4) 12 (7) 10 (6) 5 (3) 30 (5)
Inﬂuenza 5 (6) 7 (4) 7 (4) 6 (3) 25 (4)
RSV 0 (0) 2 (1) 5 (3) 8 (4) 15 (2)
GP indicates gram-positive; GN, gram-negative; HSV, herpes simplex virus; CMV, cytomegalovirus; EBV, EpsteineBarr virus; ADV, adenoviral; PIV, parainﬂuenza
virus; RSV, respiratory syncytial virus.
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HSCT
Of the 759 patients in the cohort, 60 (8%) died primarily
due to infections. Eight patients (1%) died within 30 days, 24
of 735 patients (3%) between 31 to 100 days, and 28 of 622
patients (4%) died 100 days to 2 years posttransplantation. Ofthe infectious causes, bacterial, fungal, viral, and parasitic
infections caused 12 (20%), 32 (53%), 14 (24%), and 2 (3%)
deaths, respectively.
Bacterial causes included 9 deaths due to GN and 3 due
to GP bacteremia and sepsis. Aspergillus spp caused 24 of
the 28 deaths due to mold infections, A. ﬂavus accounted
Figure 1. Percentage of patients with bacterial, fungal, and viral infections 0 to 30 days (A), 31 to 100 days (B), and 101 days to 2 years posttransplantation (C).
A, There were 73 (10)/25 (3) patients with gram-positive (GP)/gram-negative (GN; P < .0001), 20 (3)/28 (4) patients with yeast/mold (M; P ¼ .14), 12 (2)/19 (3)
patients with candidemia (Cand)/proven aspergillus (Asperg; P ¼ .21), 52 (7)/40 (5)/6 (1)/22 (3) patients with herpes simplex virus (HSV)/cytomegalovirus (CMV)/
Epstein-Barr virus (EBV)/adenovirus (ADV; P < .0001), and 14 (2)/6 (1)/7 (1) patients with parainﬂuenza (PIV)/inﬂuenza (Inﬂ)/respiratory syncytial virus (RSV; P ¼ .49)
infection of a total of 759 patients. B, There were 112 (16)/33 (4) patients with GP/GN (P < .0001), 18 (3)/28 (4) patients with yeast/mold (P ¼ .12), 5 (<1)/11 (1)
patients with Cand/Asperg (P ¼ .13), 10 (1)/65 (9)/23 (3)/19 (3) patients with HSV/CMV/EBV/ADV (P < .0001), and 8 (1)/1 (0.1)/10 (1) patients with PIV/Inﬂ/RSV
(P ¼ .03) infection of a total of 735 patients. C, There were 121 (19)/62 (10) patients with GP/GN (P < .0001), 39 (6)/43 (7) patients with yeast/mold (P ¼ .57), 9 (1)/
19 (3) patients with Cand/Asperg (P ¼ .08); 14 (2)/14 (2)/7 (1)/20 (3) patients with HSV/CMV/EBV/ADV (P ¼ .12), and 30 (5)/25 (4)/15 (2) patients with PIV/Inﬂ/RSV
(P ¼ .10) infection of a total of 622 patients. Percentages are indicated in parenthesis. Yeast infections include those in blood and other sites. Mold infections include
Aspergillus, non-Aspergillus molds, and probable invasive fungal infections.
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deaths, and C. albicans and non-albicans Candida spp caused
2 deaths each. PIV accounted for 4 of the 6 deaths due to
respiratory viruses; ADV and CMV led to 6 and 2 deaths,
respectively. Deaths due to parasitic infections included 1
patient with toxoplasmosis and another with roundworm
infestation and pulmonary artery embolization. In multiple
Cox regression analyses, severe aGVHD (P ¼ .003; OR, 2.26;
95% CI, 1.33-3.86) and age at transplantation (P ¼ .03; OR,
1.05; 95% CI, 1.00-1.11) were risk factors for infection-
related mortality.DISCUSSION
This study retrospectively looked at the infectious
complications of allogeneic HSCT performed over a 20-year
period in a cohort of 759 patients, mostly children and
adolescents (77%) with a few infants (15%) and young adults
(8%). MRD and MUD transplantations were equally repre-
sented. Approximately two-thirds received TBI-based
conditioning. There were a large number of haploidentical
donor transplantations, mostly performed after 2000; 48%
received a T cell-depleted product, and a PBSC product was
given to one-quarter of the patients, all after 2000.
Table 3
Multiple Logistic Regression Analyses of Factors Increasing the Risk for Bacterial, Fungal, Viral Infections, and Bacteremia 0-30 Days, 31-100 Days, and 101 Days to
2 Years Posttransplantation
0 to 30 Days 31 to 100 Days 101 Days to 2 Years
Variable (P value; OR, 95% CI)
Bacterial infections
aGVHD (.002; 1.98; 1.3-3.0) cGVHD (.0006; 2.05; 1.36-3.09)
Era (.0006) PBSC (.01; 2.57; 1.25-5.31)
(.004; 2.44; 1.34-4.43)*
(.0003; 3.68; 1.82-7.44)y
(.0002; 4.12; 1.94-8.73)z
Bacteremia
aGVHD (.006; 2.12; 1.26-3.56) cGVHD (.0005; 2.59; 1.53-4.37)
Era (.002) PBSC (.02; 2.84; 1.2-6.71) CMV D/R status (.04)
(.001; 3.50; 1.63-7.52)*
(.0006; 4.14; 1.85-9.27)y
(.02; 2.37; 1.16-4.84)z
Fungal infections
- aGVHD (.0008; 3.43; 1.7-6.9) cGVHD (<.0001; 2.95; 1.75-4.97)
Older age (.03; 1.72; 1.04-2.87)
Viral infections
CMV D/R status CMV D/R status (.03) cGVHD (.009; 1.80; 1.16-2.80)
(.0004) Erax (.001; 0.41; 0.24-0.71)
MRD (.001; 0.43; 0.26-0.73)
OR indicates odds ratio; CI, conﬁdence interval; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; PBSC, peripheral blood stem
cell product; CMV D/R, cytomegalovirus donor/recipient; MRD, matched-related donor.
* 1990-1994 vs 1995-1999.
y 1990-1994 vs 2000-2004.
z 1990-1994 vs 2005-2009.
x 1995-1999 vs 2005-2009.
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3 time periods posttransplantation. No signiﬁcant difference
was noted in the incidence of GP vs GN bacteremia across
eras. Mortality attributed to bacteremia was 6%. Bacterial
infections and bacteremia were signiﬁcantly higher in 1990
to 1994 compared with later eras, in the 0- to 30-day time
period. The decrease in bacterial infectionsmay be attributed
to earlier engraftment, better supportive care, improved
patient education, and scrupulous attention to hand
hygiene in later time cohorts. None of the patients received
routine prophylaxis with ﬂuoroquinolones. Increasing GN
bacteremia with ﬂuoroquinolone resistance has been re-
ported with the use of ﬂuoroquinolone prophylaxis in adults,
with a mortality of 11.3% [21]. Prophylaxis was associated
with a GP/GN ratio of 1.0, incidence of E. coli bacteremia of
62% among GN rods, and E. faecium of 9%, compared to a GP/
GN ratio of 1.4, incidence of E. coli bacteremia of 34% and
E. faecium of 3% in our series. Higher mortality in adults may
be due to increased Enterobacteriacae and E. faecium asso-
ciated with high attributable mortality rates. Other factors
contributing to increased mortality in adults may include
presence of comorbid conditions and higher incidence of
GVHD.
Severe aGVHD was associated with bacteremia and
bacterial infections 31 to 100 days post-HSCT; cGVHDTable 4
Inﬂuence of D/R CMV Status on the Risk of Viral Infections at 0-30 and 31-
100 Days Posttransplantation
CMV D/R status P value OR 95%CI
0-30 days
/þ vs þ/þ .003 0.45 0.26-0.76
/þ vs þ/ .0003 0.33 0.19-0.6
þ/ vs / .004 2.10 1.27-3.49
31-100 days
þ/þ vs / .006 1.92 1.21-3.08
D/R indicates donor/recipient; CMV, cytomegalovirus; OR, odds ratio; CI,
conﬁdence interval.increased the risk for bacterial infections late after trans-
plantation. An independent association between blood-
stream infections and aGVHD has been previously observed
[22,23]. Elaboration of cytokines after bacteremia could
potentially increase the risk for aGVHD. Use of immune-
suppressive medications for GVHD may increase the risk of
bacteremia.
Recipients of a PBSC product had a higher incidence of
bacteremia and bacterial infections 31 to 100 days post-
transplantation. Higher aGVHD has been shown with PBSC
compared to bone marrow transplantations [24], and this
may have accounted for the increased risk. Pre-engraftment
bloodstream infections have also been associated with
a PBSC graft in a predominantly adult series of HSCT
patients [25]. The higher incidence of bacteremia in adults
may be related to the increased use of PBSC grafts.
Infections by Aspergillus spp were equally represented in
all time periods posttransplantation, were the dominant
fungi causing infection, and were associated with high
mortality. Two- thirds of cases of aspergillosis were seen
after engraftment, which is consistent with adult studies
[26,27]. The shift from early to late aspergillosis may be
a result of the use of PBSC grafts and RIC, with attenuated
cytopenias. Non-Aspergillus mold infections were
uncommon, as previously observed [5]. Increased mold
infections noted from 2005 to 2009 were largely due to
diagnosis of probable invasive fungal infection based on
a positive assay for galactomannan. Candidemia was equally
distributed among C. albicans and non-albicans Candida spp,
and was equally prevalent in all time periods. Severe aGVHD
and cGVHD increased the risk of fungal infections. GVHD has
previously been associated with an increased risk of asper-
gillosis in adults [28], perhaps related to impaired neutrophil
and cellular immunity and use of corticosteroids.
An increased risk for aspergillosis has also been shown in
older adult patients [29]. Our data support the increased risk
of fungal infections with older age. T cell receptor
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signiﬁcantly higher in patients younger than 19 years of age
as compared to older patients [30]. Low TREC values corre-
lated with severe opportunistic infections in the ﬁrst month
posttransplantation and extensive cGVHD [30]. Low TREC
values have also been associated with a higher incidence of
CMV infection [31]. CMV disease has also been shown to be
associated with an increased risk for late invasive aspergil-
losis [28].
CMV viremia in our study was seen in 5% of patients pre-
engraftment and in 9% 31 to 100 days posttransplantation.
Adenoviremia was detected equally in all time periods. The
16% rate of CMV detection in our cohort, in which only half
the patients received T cell- replete HSCT, is comparable to
the 28% rate of detection reported in a cohort of 40 children
after allogeneic T cell- replete HSCT [32]. Viral DNAemia was
seen after neutrophil engraftment and predominantly up to
day þ100 [32]. The higher rate of viral infections between
2005 and 2009 may be due to better surveillance and
improved diagnostic methods. The predominance of respi-
ratory viral infections late after transplantation is a novel
observation, which needs corroboration from other studies.
Patients with CMV Dþ/R status had a higher risk of all
viral infections at day 0 to 30 and those with Dþ/Rþ status at
day 31 to 100. Previous studies have conﬁrmed the high risk
of CMV viremia with D/R seropositivity, as seen in our study
[33]. Dþ/R patients have been shown to have higher
transplantation-related mortality as compared to D/R
patients, predominantly associated with bacterial and fungal
infections [30]. A bidirectional relationship has also been
observed between CMV replication and aGVHD [34].
Haploidentical donor HSCT was not associated with an
increased risk of infections. In the ﬁrst phase II study of
haploidentical donor HSCT in adults with acute leukemia
conditioned with a TBI-based regimen, 26% died from
infectious causes, mainly CMV (13%) and fungal infections
(5%) [35]. An RIC regimen in our institution using ﬂudar-
abine, thiotepa, and melphalan with T cell depletion, led to
rapid immune reconstitution with less viremia and aGVHD
[36]. Close monitoring for viral and fungal infections,
prophylaxis, and pre-emptive therapy may have also
contributed to reducing the risk of infection in these patients.
Infections 100 days to 2 years post-HSCT caused the
highest mortality (4%) of the 3 time periods post-HSCT. Late
infections have also been shown to be an important
contributor to mortality due to infection in predominantly
adult patients who undergo HSCT, with aGVHD as the most
important risk factor [37], similar to our results. Other risk
factors for mortality included cGVHD and CMV infection [37].
Our study has several limitations. Cord blood trans-
plantations were excluded from the analysis, as they were
few in number. This is a major limitation, as infection and
immune reconstitution are very different in cord trans-
plantations, which represent a signiﬁcant donor group in the
pediatric population. Further, the patient population was
heterogeneous, small numbers of infections precluded
analyses within each subgroup, analyses were retrospective,
only microbiologically documented infections were
included, antifungal, antiviral prophylaxis, and methods for
detection of viremia differed across the 2 decades. Parasitic
infections were few in number.
There seems to be a continuum in the timeline of infec-
tions posttransplantation in our institution, with bacterial,
fungal, and viral infections prevalent in all time periods,
particularly late after the transplantation, the risk affected byGVHD, CMV D/R status, product type, older age, and use of
unrelated donors. This contrasts with the conventional
teaching of increased bacterial infections and Candidemia in
the pre-engraftment phase followed by aspergillosis, CMV,
and respiratory virus infections postengraftment, and
decreased vulnerability to infections in the late post-
transplantation period. Prospective studies with inclusion of
cord and haploidentical transplantations are needed to
conﬁrm these observations.
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